Alzheimer’s disease today impacts over 46 million people globally, reaching 74.7 million in 2030 and projected to grow to over 131 million people by 2050 with an economic impact to exceed two trillion dollars.
Leveraging the proprietary Cytox variaTECT™ SNP genotyping array, Cytox SNPfitR™ interpretive software for polygenic risk scoring and running on the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform from Thermo Fisher Scientific, Cytox offers genomic profiling testing assays and services to early access collaborators in academia and biopharma pursuing clinical research and drug development. The service is designed to help researchers and clinicians access the biology and genetics behind dementia, stratify patients to enable more cost effective and information rich clinical trials, and ultimately establish risk for cognitive decline and matching with the most appropriate targeted therapy.
The NPIF funding will allow the business to further develop its commercial offering and create four new jobs in the Manchester region. Funding will also support the development of new diagnostics across the dementia sector with the objective of transforming the prospects for cost-effective identification of subjects for clinical trials and for timely treatment.
Could NPIF Maven Equity Finance help fund your growth journey?
If you’re running a business that’s looking to grow, we’d love to hear from you. Feel free to give us a call to find out more about our flexible funding solutions:
0191 731 8595
